- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03693092
LAmbre™ Left Atrial Appendage Closure System Follow-Up Study
LAmbre™ Left Atrial Appendage Closure System Post-Market 2-5 Years Follow-Up Study
Studieoversikt
Status
Forhold
Detaljert beskrivelse
All subjects who completed 1-year follow-up of the LAmbreTM LAA system registration trial will be conducted 2 years, 3 years, 4 years and 5 years follow-up by the telephone call.
During the follow-up, the investigator or his/her designee will use a standardized form to record the occurrence of the subject's safety events and validity endpoint by telephone,and complete the safety and efficacy summary report. The endpoints of the study included compound events, MACCE events, stroke, haemorrhage and other events.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Chengdu, Kina
- West China Hospital, Sichuan University
-
Ta kontakt med:
- Jian Jiang
-
-
Beijing
-
Beijing, Beijing, Kina
- Beijing Chaoyang Hospital, Capital Medical University
-
Beijing, Beijing, Kina
- Fuwai Hospital Chinese Academy of Medical Science
-
Ta kontakt med:
- Yan Yao
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina
- The 2nd Affiliated Hospital of Harbin Medical University
-
Ta kontakt med:
- bo Yu
-
-
Hubei
-
Wuhan, Hubei, Kina
- Wuhan Asia Heart Hospital
-
Ta kontakt med:
- Xi Su
-
Wuhan, Hubei, Kina
- People's Hospital of Wuhan University
-
Ta kontakt med:
- Congxin Huang
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Jiangsu Province Hospital
-
Ta kontakt med:
- Minglong Chen
-
-
Liaoning
-
Shenyang, Liaoning, Kina
- The General Hospital Of Shenyang Military Region
-
Ta kontakt med:
- Zulu Wang
-
-
Shandong
-
Dalian, Shandong, Kina
- The First Affiliated Hospital of Dalian Medical University
-
Ta kontakt med:
- Yanzong Yang
-
-
Shanghai
-
Shanghai, Shanghai, Kina
- Shanghai Tenth People's Hospital
-
Ta kontakt med:
- Yawei Xu
-
Shanghai, Shanghai, Kina
- Xinhua Hospital Affiliated Shanghai Jiaotong University School of Medicine
-
Ta kontakt med:
- Yigang Li
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients who participated in the LAmbreTM Safety and Efficacy Study and completed the 1-year follow-up.
The inclusion criteria of LAmbreTM Safety and Efficacy Study:
- Age>=18, CHADS2 score>=1
- Patients cannot be treated long-term with Warfarin
- Eligible for clopidogrel and aspirin
- Provide written informed consent and agree to comply with the required follow-ups
Exclusion Criteria:
- Exclusion criteria: Patients who did not participate in the LAmbreTM Safety and Efficacy Study or did not complete 1-year follow-up LAmbreTM Safety and Efficacy Study.
The exclusion criteria of LAmbreTM Safety and Efficacy Study:
- Need to take Warfarin
- Presence of rheumatic, degenerative or congenital valvular heart diseases
- Early stage or paroxysmal atrial fibrillation
- Symptomatic patients with carotid artery disease (such as carotid stenosis>=50%)
- Heart failure NYHA grade IV
- Recent 30 days stroke or TIA
- Presence of active sepsis or endocarditis
- Cardiac tumours or other malignancy with estimated life expectancy <2 years
- Abnormal blood test; renal dysfunction
- LAA removed or heart implant patients
- Patients have planned electrophysiological ablation or cardioversion 30 days post implantation of the LAmbre system
- Patients have a history of mechanical prosthesis operation
- Patients who are pregnant, or desire to be pregnant during the during the study
- Participation in other trials
- A known allergy to nitinol
- Patients will not be able to complete the trial
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The incidence of compound event
Tidsramme: 5 years after the surgery
|
The compound event including death, systemic embolization, complications related to the device and requiring treatment (cardiac embolism, embolization, stroke, hemorrhage, death).
|
5 years after the surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The incidence of MACCE events
Tidsramme: 2,3,4,5 years postoperative follow-up.
|
The MACCE events including death (All cause death, All-cause death includes cardiac death, non-cardiac death and unexplained death), stroke, cardiac tamponade, and renal failure.
|
2,3,4,5 years postoperative follow-up.
|
Ischemic stroke rate
Tidsramme: 2,3,4,5 years postoperative follow-up
|
Ischemic stroke is a neurological deficit caused by transient ischemic attack, cerebral thrombosis or cerebral embolism.
|
2,3,4,5 years postoperative follow-up
|
The rate of stroke
Tidsramme: 2,3,4,5 years postoperative follow-up
|
Stroke is deviated into ischemic, hemorrhagic or undetermined stroke, and transient ischemic attacks (TIA).
|
2,3,4,5 years postoperative follow-up
|
The event of bleeding
Tidsramme: 2,3,4,5 years postoperative follow-up
|
Intracranial or alimentary canal, or any bleeding that requires transfusion of 2 units of red blood cell suspension.
|
2,3,4,5 years postoperative follow-up
|
Cardiac events
Tidsramme: 2,3,4,5 years postoperative follow-up
|
Non-fatal myocardial infarction, arrhythmia, cardiac tamponade, cardiogenic shock, endocarditis.
|
2,3,4,5 years postoperative follow-up
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Congxin Huang, People's Hospital of Wuhan University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LAA 2-5ys FU
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Atrieflimmer
-
Pusan National University HospitalHar ikke rekruttert ennåHjerteimplanterbar elektronisk enhet | Atrial High Rate EpisodeKorea, Republikken
-
The Second Affiliated Hospital of Chongqing Medical...UkjentAtrieflimmer | Hjerteombygging, atrial | Sacubitril/Valsartan
-
W.L.Gore & AssociatesFullført
-
Helios Klinikum PforzheimRekrutteringHøyre hjertesvikt | Trikuspidal regurgitasjon | Hjerteombygging, Ventrikulær | Hjerteombygging, atrialTyskland
-
Henry Ford Health SystemTilbaketrukket
-
Nobles Medical Technologies II IncPåmelding etter invitasjonForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater, Italia
-
HeartStitch.ComUkjentForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater
-
China National Center for Cardiovascular DiseasesRekrutteringHjertesykdommer | Atrial septal dilatasjonKina
-
Assiut UniversityUkjent
-
Amsterdam UMC, location VUmcRekruttering